Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
JDT: I really hope that's the reality. Granted, I don't think there is any competition in this category that is any closer to market. I think my expectations were that this would become a driving, focal project for moonshot, and the i's would be dotted and the t's crossed with all haste. Instead the ELISA RNS only confirmed that Avacta still didn't even have a physical pilot batch yet. The allusions to affimer performance were great, but it's the rapid test and results that matter.
Could anyone provide some assurance that we're within expected timelines for validation?
It's over a month since the partnership with Liverpool for clinical validation was announced, and a month is 4320 lots of 10 minutes (assuming all testing is serial rather than parallel, which it wouldn't be).
Either the pilot batches aren't physically available yet from manufacturers, the testing is outrageously slow for such a globally redefining product, or testing should have wrapped up a long time ago. Respectively they are worrying, disappointing, and confusing as I'd have expected an RNS by now with something alluding to the confirmed S&S.
If this product produces such a rapid response, why is it taking so long to test? Inb4 calls that I'm a deramper, I'm heavily invested and waiting for this to kick start society. I just thought we'd be there by now.
If the BOD receives an offer... Followed by an immediate counter offer... And then one party raises $500m to up their initial offer....
Does the BOD only need to RNS accepted/viable bids to shareholders? Would each successive offer be RNS'd? Or does the dust settle and then a single yes/no is put to shareholders?
Tomorrow is my Birthday, and I'd be very grateful to the BOD if they could deliver the best present we've all been hoping for.
I'll be sinking a few fortified wines on the banks of the Douro come what may, but I'll be reaching for the top shelf if the good ship EUA floats into harbour.
I'm very sorry all, I managed to talk a couple of friends into investing here... Knowing my luck the recent drop was a direct consequence of that.
On the plus side I'm prepared to take that on the chin, and I see this as an ace buying opportunity. It can't be too much longer before validation results come rolling in from LSTM, and I'm going to be saying I told ya so when it curves back up again.
N.B. that's the SP going up, not the infection rates...
N.B. actually, both
Also to all of those who thought it was unfair that BBI (manufacturing partner) was putting up job adverts specifying "antibody" tests, this tweet last night went out as confirmation that AVCT are in no way being left out in the cold
https://twitter.com/bbi_solutions/status/1297896901132587011?s=19
I would have thought that seeing as the only certain customer app is Triller, which is a relatively direct competitor to Snapchat, there would be some form of exclusivity agreement preventing signing of Snap Inc. as a client. Apple Radio would not be a competitor.
Nothing for certain, obviously, but only one of those makes business sense for both clients
Try reading some of the actual BBI job postings. A couple reference Antibody only, the vast majority are less specific and concern various roles in QC and technical improvement. That's not antibody specific, that's ramping-up-production-capacity specific.
A manufacturer wouldn't be running up works unless they're very confident of approval.
"Consortium (UK-RTC) partners require more staff to meet production demands in advance of final approval of the test by regulatory authorities"
This makes it sound certain, I love it. I want to make money, sure. More importantly I think this could genuinely be revolutionary in our handling of the pandemic.
Without being slated as a "deramper", I had a question for those better informed about this recent placing.
Due to the massive real estate currently under license or pending application, it feels as though the current SP is still cheap. That being said, the BOD chose now to generate more shares for financing ongoing work.
To me that suggests that there likely won't be any further license RNS prior to an announcement of preferred offer, else there would have been opportunities to gain more funding for the same degree of dilution.
Or this is a favour to IIs who want into the game ASAP for short term gains, in case there are license announcements imminent... Though this would be bordering on insider trading.
Or, the finances are currently dire enough that the $10.5m was urgently needed.
Does anyone have any evidence to suggest any of these being more likely?
What on earth would a company which has publicly declared it's shopping for buyers need a placing for. Especially one that already have a $150m contract in place to action at any time if they decide to make a run of it themselves
Anyone who thinks COVID19 is dwindling into nothing, please have a listen of The Daily podcast episode from the NYT yesterday (what we've learned about the coronavirus).
Also any news outlet about New Zealand losing its 0-case status because they lacked the very on-the-spot test Avacta is creating.
It's a real shame that you've nicked a good username LochRNSMonster, as I hope to never see it again on his board.
Google shows the latest trade it knows about, but that's not necessarily the most recent trade within hours. Could be from days ago that's just been notified.0
Alistair is explaining how this platform can not only improve cancer treatments within their existing treatment schedule, but also reduce toxicity such that current drugs can target a much wider range of cancers. Cancer treatments are a huge market, and they're absolutely awful... any way of improving efficacy, comfort, and market for these is fantastic.
Just think about it - if even one of these treatments work it will become the global default drug overnight. And half of all humans are likely to have cancer at some point in their lives.
Can't explain why the SP always drops on fantastic news, it's a little bit upsetting, but the core product is absolutely there to make this a global game changer.